Related Experiment Video
Updated: Jun 25, 2026

Optimization of the Epimedii Folium Mutton-Oil Processing Technology and Testing Its Effect on Zebrafish Embryonic Development
Published on: March 17, 2023
Finerenone in Treating a 12-Year-Old Boy Suffering Gitelman Syndrome Without Causing Gynecomastia
Yuhe Yin1, Haowen Lin2, Qingqing Gao1
1Department of Nephrology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangdong, China.
Finerenone, a non-steroidal MRA, effectively treated Gitelman syndrome in a child without causing gynecomastia. This approach improved potassium levels and avoided side effects seen with steroidal MRAs.
Area of Science:
- Nephrology
- Pediatric Endocrinology
- Genetics
Background:
- Gitelman syndrome (GS) is an autosomal recessive disorder affecting ion transport, leading to hypokalemia and hypomagnesemia.
- Non-steroidal mineralocorticoid receptor antagonists (MRAs) like finerenone show promise in kidney disease, but data in pediatric non-diabetic nephrology is limited.
- Steroidal MRAs can cause side effects such as gynecomastia in children.
Related Concept Videos
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome III : Nursing Management